Skip to main content

Day: March 20, 2022

Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and Delta Variants

Sorrento scientists have perfected the expression of the spike protein to potentially improve the safety profile of the COVID-19 mRNA vaccines by incorporating a furin cleavage site mutation to prevent leakage of S1 subunit into the blood circulation targeting vital organ tissues with ACE2 receptors for the spike proteins that may in part cause the undesirable side effects. Sorrento’s designer mRNA vaccine, utilizing a chimeric mRNA that incorporates the Delta receptor binding domain (RBD) into the Omicron spike protein, provided strong, broad-spectrum protection against both BA.1 and BA.2 sublineages of Omicron, and Delta variant in immunized animals. Sorrento intends to develop and seek EUA approval of this next-generation mRNA vaccine in Mexico and other developing countries.SAN DIEGO, March 20, 2022 (GLOBE NEWSWIRE) — Sorrento...

Continue reading

Imperial Petroleum Announces Pricing of Upsized $60 Million Underwritten Public Offering

ATHENS, Greece, March 20, 2022 (GLOBE NEWSWIRE) — Imperial Petroleum Inc. (Nasdaq: IMPP) (the “Company”) announced today the pricing of an upsized underwritten public offering of 37,500,000 units at a price of $1.60 per unit. Each unit consists of one common share (or prefunded warrant in lieu thereof) and one Class B warrant to purchase one common share, and will immediately separate upon issuance. The gross proceeds of the offering to the Company, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $60 million. The Company intends to use the net proceeds of the offering for capital expenditures, including acquisitions of additional vessels which we have not yet identified, and for other general corporate purposes. Each Class B warrant is immediately exercisable for one...

Continue reading

Barrick, Pakistan and Balochistan Agree in Principle to Restart Reko Diq Project

ISLAMABAD, Pakistan, March 20, 2022 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) and the governments of Pakistan and Balochistan have reached agreement on a framework that provides for the reconstitution of the Reko Diq project in the country’s Balochistan province. The project, which was suspended in 2011 due to a dispute over the legality of its licensing process, hosts one of the world’s largest undeveloped open pit copper-gold porphyry deposits. The reconstituted project will be held 50% by Barrick and 50% by Pakistan stakeholders, comprising a 10% free-carried, non-contributing share held by the government of Balochistan, an additional 15% held by a special purpose company owned by the government of Balochistan and 25% owned by other federal state-owned enterprises. A separate agreement provides for Barrick’s...

Continue reading

Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress

BOTHELL, Wash., March 20, 2022 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that study overview and baseline data from ACT-AD, a fully enrolled Phase 2 clinical trial of Athira’s lead development candidate, fosgonimeton (ATH-1017) in study participants with mild-to-moderate Alzheimer’s disease (AD), were presented in an oral presentation at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Diseases (AD/PD™ 2022) taking place in Barcelona, Spain, and virtually from March 15-20, 2022. Of the 77 study participants enrolled in the randomized, double-blind, placebo-controlled trial, the mean age is 71.4 years, with 50.6% female...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.